Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Barzolvolimab in Moderate to Severe Atopic Dermatitis
NCT06727552Phase 2Active, not recruiting
- Sponsor
- Celldex Therapeutics
- Start
- Dec 2024
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of barzolvolimab in atopic dermatitis (AD), sponsored by Celldex Therapeutics. Started Dec 2024; status: active, not recruiting.
02
Drugs
barzolvolimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06727552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06727552.